We are live on ! Find out more
IBRX icon

ImmunityBio

49 hedge funds and large institutions have $17.5M invested in ImmunityBio in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 12 increasing their positions, 18 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

14% more capital inflows, than outflows

Capital inflows: $3.54M | Capital outflows: $3.11M

4% more funds holding

Funds holding: 47 → 49 (+2)

0.35% more ownership

Funds ownership: 5.84% → 6.19% (+0.35%)

10% less call options, than puts

Call options by funds: $316K | Put options by funds: $351K

33% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 18

Holders
49
Holders Change
+2
Holders Change %
+4.26%
% of All Funds
1.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
12
Reduced
18
Closed
12
Calls
$316​K
Puts
$351​K
Net Calls
-⁠$35​K
Net Calls Change
+$180​K

IBRX Hedge Fund Activity: Q1 2020 in Review

49 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2020, worth a combined $17.5M — down 19% from $21.8M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IBRX positions and 12 closed out — a net gain of 2 holders — while 12 added to existing stakes and 18 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $1.14M. The largest seller was JP Morgan Chase, cutting an estimated $633K.

  • 49 institutional investors held ImmunityBio (IBRX) as of Q1 2020, up from 47 in Q4 2019.
  • Funds reported $17.5M of ImmunityBio stock for Q1 2020, down 19% quarter-over-quarter.
  • 14 funds opened new ImmunityBio positions in Q1 2020 and 12 closed out, a net change of +2 holders.
  • The largest ImmunityBio buyer in Q1 2020 was Susquehanna International Group, an estimated $1.14M added.
  • The largest ImmunityBio seller in Q1 2020 was JP Morgan Chase, an estimated $633K sold.

Based on aggregated 13F filings for Q1 2020.